Rifaximin for the Treatment of Persistent Symptoms in Patients With Celiac Disease
Status:
Completed
Trial end date:
2008-04-01
Target enrollment:
Participant gender:
Summary
Celiac disease is a condition in which the small intestine is damaged by gluten, the storage
protein of wheat and similar proteins in barley and rye. The disease can cause different
symptoms such as diarrhea, bloating, abdominal pain and weight loss. The majority of patients
respond to a gluten-free diet. However some patients (5-30%) have persistent symptoms and are
considered to be poor responders to the diet. Bacterial overgrowth in the small intestine
accounts for some of the refractory patients.
This study seeks to determine if antibiotic therapy with rifaximin relieves the symptoms of
patients who are poorly responsive to a gluten-free diet and whether this impacts their
breath test results.
Phase:
N/A
Details
Lead Sponsor:
Columbia University
Collaborators:
Bausch Health Americas, Inc. Valeant Pharmaceuticals International, Inc.